It appears that Pharmaceutical stocks are doing well in the wake of Obamacare. The biotech index seems to be to the plus side as well. This is important information as the Intrade contract on health care reform passing was significantly lower when the market closed on Friday.

My primary concerns surrounding the healthcare overhaul is that it would lead to shrinking profits in pharma and biotech. As of right now that doesn’t seem to be a major fear.